Medicare Coverage for GLP-1s Cometh: KOL Call Highlights Program Puts and Takes

Research evidence excerpt

Medicare Coverage for GLP-1s Cometh: KOL Call Highlights Program Puts and Takes

The pharmacy channel could be the biggest near-term source of friction, particularly because the

program appears to be NDC-specific. Treff highlighted a nuanced, but important, operational issue:

the bridge program may cover only specific NDCs for each product, even where the underlying drug

and package are otherwise identical. This creates a risk that pharmacies have the wrong NDC on the

shelf, leading to delays, rejected claims, or future rebate complications. In mixed Medicare/commercial

geographies, pharmacies may also face inventory complexity if Medicare-specific NDCs are stocked for

bridge patients, but commercial plans later reject rebate claims tied to those same NDCs. Treff’s view

was that this should not derail the program, but it could create early launch friction as pharmacies learn

which products to order and how to route claims appropriately.

Humana’s administrative role is just that--adminstrative (and unlikely to be a hindrance or undue

barrier to access), but the broader system still creates multiple points of confusion for patients

and physicians. Reid viewed Humana’s role as relatively straightforward: receive the claim, reject

initially where required (this expected as the next step is key), process the prior authorization, confirm

eligibility, and enable reimbursement (put more simply they are just controlling the flow of funds).

The more difficult challenge sits upstream and downstream to the actual drug acquisition

transaction. Physicians need to know that eligible obesity patients should not simply be routed through

standard Part D pathways, and pharmacists need to understand when to send claims through the bridge